GPN Vaccines has raised $18 million!

Australian start-up GPN Vaccines has raised $18 million in their latest capital raise, achieving a significant $300 million valuation.

The company is developing a vaccine against one of the world’s most prolific bacterial pathogens, Pneumococcus, which kills about 1 million people each year and is responsible for a wide range of illnesses, including middle ear infections and pneumonia. The team plans to use some of the funds for further clinical studies in Australia.

You can read the full media release here or follow GPN Vaccines’ journey by connecting with them on LinkedIn.